版本:
中国

BRIEF-Merck receives CHMP positive opinion recommending approval of isentress

May 19 Merck & Co Inc:

* Merck receives chmp positive opinion recommending approval of isentress® (raltegravir) 600 mg in the european union

* Merck receives chmp positive opinion recommending approval of isentress® (raltegravir) 600 mg in the european union

* Merck & Co Inc - decision on approval is expected in second half of 2017

* Says a decision on approval is expected in second half of 2017

* Merck & Co Inc - once daily formulation of isentress is currently under review in united states by food and drug administration Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐